Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression|
|Citation:||Progress in Neuro-psychopharmacology & Biological Psychiatry, 2008; 32(1):224-228|
|Publisher:||Pergamon-Elsevier Science Ltd|
|Katharina Domschke, Christa Hohoff, Lena S. Mortensen, Tilmann Roehrs, Jürgen Deckert, Volker Arolt, Bernhard T. Baune|
|Abstract:||The monoamine oxidase A (MAO-A) has been suggested to be involved in the pathogenesis as well as the pharmacological treatment of Major Depression. In the present study, 340 patients with a Major Depressive Episode (f=194, m=146; DSM-IV) of Caucasian descent were genotyped for the functional MAO-A VNTR. The clinical response to antidepressive pharmacological treatment was assessed by weekly intra-individual changes of HAM-D-21 scores over six weeks. The longer MAO-A alleles (3a, 4, 5) conferred a significant risk of slower and less efficient overall response over the course of 6 weeks of antidepressant treatment in patients with Major Depression, with the effect being restricted to female patients (p=0.028; corrected for multiple testing). The present results suggest that high-activity MAO-A genotypes possibly by consecutively decreased serotonin and/or norepinephrine availability negatively influence antidepressant treatment response during the first six weeks of pharmacological treatment in female patients with Major Depression.|
|Keywords:||Antidepressant treatment; Major Depression; Monoamine oxidase A; Pharmacogenetics; VNTR|
|Rights:||© 2007 Elsevier Inc. All rights reserved.|
|Appears in Collections:||Psychiatry publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.